The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).

DiRECT Diabetes remission Metabolomics Randomised controlled trial Type 2 diabetes Weight loss

Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 13 02 2023
accepted: 04 08 2023
pubmed: 25 10 2023
medline: 25 10 2023
entrez: 25 10 2023
Statut: ppublish

Résumé

High-throughput metabolomics technologies in a variety of study designs have demonstrated a consistent metabolomic signature of overweight and type 2 diabetes. However, the extent to which these metabolomic patterns can be reversed with weight loss and diabetes remission has been weakly investigated. We aimed to characterise the metabolomic consequences of a weight-loss intervention in individuals with type 2 diabetes. We analysed 574 fasted serum samples collected within an existing RCT (the Diabetes Remission Clinical Trial [DiRECT]) (N=298). In the trial, participating primary care practices were randomly assigned (1:1) to provide either a weight management programme (intervention) or best-practice care by guidelines (control) treatment to individuals with type 2 diabetes. Here, metabolomics analysis was performed on samples collected at baseline and 12 months using both untargeted MS and targeted Decreases in branched-chain amino acids, sugars and LDL triglycerides, and increases in sphingolipids, plasmalogens and metabolites related to fatty acid metabolism were associated with the intervention (Holm-corrected p<0.05). In individuals who lost more than 9 kg between baseline and 12 months, those who achieved diabetes remission saw greater reductions in glucose, fructose and mannose, compared with those who did not achieve remission. We have characterised the metabolomic effects of an integrated weight management programme previously shown to deliver weight loss and diabetes remission. A large proportion of the metabolome appears to be modifiable. Patterns of change were largely and strikingly opposite to perturbances previously documented with the development of type 2 diabetes. The data used for analysis are available on a research data repository ( https://researchdata.gla.ac.uk/ ) with access given to researchers subject to appropriate data sharing agreements. Metabolite data preparation, data pre-processing, statistical analyses and figure generation were performed in R Studio v.1.0.143 using R v.4.0.2. The R code for this study has been made publicly available on GitHub at: https://github.com/lauracorbin/metabolomics_of_direct .

Identifiants

pubmed: 37878066
doi: 10.1007/s00125-023-06019-x
pii: 10.1007/s00125-023-06019-x
pmc: PMC10709482
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-87

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202802/Z/16/Z
Pays : United Kingdom
Organisme : Diabetes UK
ID : 13/0004691
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Diabetes Care. 2022 Apr 1;45(4):1013-1024
pubmed: 35349649
Bioinformatics. 2022 Mar 28;38(7):1980-1987
pubmed: 35134881
J Nutr. 2001 Mar;131(3s):968S-71S
pubmed: 11238798
Obesity (Silver Spring). 2016 Dec;24(12):2451-2466
pubmed: 27891833
PLoS One. 2014 Jul 02;9(7):e101267
pubmed: 24988418
Diabetes Care. 2020 Jul;43(7):1537-1545
pubmed: 32345654
J Physiol Biochem. 2014 Jun;70(2):593-602
pubmed: 24402878
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000588
pubmed: 27148576
Cell Metab. 2019 Feb 5;29(2):488-500.e2
pubmed: 30318341
Mol Biosyst. 2015 Jul;11(7):1742-74
pubmed: 25919044
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):335-343
pubmed: 30586632
Br J Nutr. 1993 Jan;69(1):169-76
pubmed: 8457525
Obes Surg. 2017 Apr;27(4):917-925
pubmed: 27738970
Circulation. 2004 Nov 9;110(19):3068-74
pubmed: 15505088
Metabolomics. 2017;13(9):104
pubmed: 28804275
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
Lancet. 2021 Jan 23;397(10271):293-304
pubmed: 33485454
Endocrine. 2013 Feb;43(1):33-40
pubmed: 22847316
Alcohol Clin Exp Res. 2005 May;29(5):781-7
pubmed: 15897723
Diabetologia. 2008 Oct;51(10):1781-9
pubmed: 18726585
PLoS Med. 2014 Dec 09;11(12):e1001765
pubmed: 25490400
J Lipid Atheroscler. 2022 Jan;11(1):20-38
pubmed: 35118020
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4233-E4240
pubmed: 28484010
Diabetes Care. 2022 Nov 1;45(11):2753-2786
pubmed: 36148880
Sci Transl Med. 2011 Apr 27;3(80):80re2
pubmed: 21525399
BMC Fam Pract. 2016 Feb 16;17:20
pubmed: 26879684
Diabetologia. 2020 Oct;63(10):2112-2122
pubmed: 32776237
Cell Metab. 2018 Oct 2;28(4):547-556.e3
pubmed: 30078554
Diabetes Care. 2014 Dec;37(12):3150-6
pubmed: 25315204
PLoS One. 2010 Nov 11;5(11):e13953
pubmed: 21085649
Int J Mol Sci. 2019 May 18;20(10):
pubmed: 31109071
Diabetologia. 2018 Mar;61(3):589-598
pubmed: 29188339
BMC Med. 2015 Mar 09;13:48
pubmed: 25857605
Diabetologia. 2012 Feb;55(2):321-30
pubmed: 22065088
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
Cells. 2021 Oct 21;10(11):
pubmed: 34831057
J Am Heart Assoc. 2020 Apr 7;9(7):e014324
pubmed: 32200717
Cell Metab. 2017 Aug 1;26(2):281-283
pubmed: 28768165
Lancet Diabetes Endocrinol. 2014 Jan;2(1):65-75
pubmed: 24622670
Nat Rev Endocrinol. 2017 Aug;13(8):443-444
pubmed: 28621336

Auteurs

Laura J Corbin (LJ)

MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK. laura.corbin@bristol.ac.uk.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. laura.corbin@bristol.ac.uk.

David A Hughes (DA)

MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Caroline J Bull (CJ)

MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Emma E Vincent (EE)

MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, UK.

Madeleine L Smith (ML)

MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Alex McConnachie (A)

Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Claudia-Martina Messow (CM)

Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Paul Welsh (P)

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

Roy Taylor (R)

Newcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

Michael E J Lean (MEJ)

Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

Naveed Sattar (N)

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

Nicholas J Timpson (NJ)

MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Classifications MeSH